APLM实时信号 | 通过Getagraph.com最大化利润

购买 130717 min ago

@ $0.675

发出时间: 9 Feb 2024 @ 22:59

回报率: -41.20%

上一信号: Feb 7 - 22:54

上一信号: 出售

回报率: 4.44 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 04:00):

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia...

Stats
今日成交量	153 431
平均成交量	176 446
市值	35.49M
EPS	$0 ( 2024-04-26 )
下一个收益日期	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.170
ATR14	$0.00200 (0.50%)

音量相关性

長: -0.18 (neutral)

短: 0.73 (moderate)

Signal:(52.354) Neutral

Apollomics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Apollomics, Inc. 相关性 - 货币/商品

0.48
( neutral )

0.55
( weak )

0.00
( neutral )

-0.23
( neutral )

Apollomics, Inc. 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.77

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.77

Financial Reports:

No articles found.

Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.